“In patients with RA, the occurrence of depression is high,” Dr Jens Kristian Pedersen (Odense University Hospital, Denmark) stated [1]. He presented a cohort study that investigated the mortality risk in patients with incident RA and depression. Data was collected from various nationwide Danish registries. The presence of depression was defined as the first filling of an antidepressant prescription. The follow-up period for the all-cause mortality risk was from January 2008 to December 2018. Included in the analysis was data on 11,071 RA patients equalling 56,993 person-years of follow-up.
About 10% of the participants (n=1,095) had a filling of antidepressants during the follow-up period. The median age was 61 years, 66% were women, and 64% had seropositive RA. There was some variance between those with and without exposure to antidepressants. “In those exposed, the age distribution was different, the fraction of women was higher, a lower fraction had seropositive RA, and the median HAQ[1] and DAS281 were higher than in those not exposed,” Dr Pedersen pointed out.
The results of the adjusted analysis for mortality hazard in RA patients with or without depression revealed the highest risk for exposed patients under the age of 55 years (HR ratio 6.66; 95% CI 2.80–15.85). Corresponding HR ratios for the other age groups receiving antidepressants were 3.3 for 55–70 years and 2.94 for >70 years old. Mortality was increased by depression in men (HR ratio 3.70) and women (HR ratio 2.91), as well as seropositive (HR ratio 3.45), and seronegative RA (HR ratio 3.08). “According to exposure status [to antidepressants], the cumulative mortality followed 2 clearly different paths: the mortality curves separated early and already within the first and second year of follow-up,” Dr Petersen further commented on the Kaplan-Meier-curves for exposed and non-exposed participants.
- Pedersen JK, et al. More than six-fold increased mortality risk in patients with incident rheumatoid arthritis and depression in a large cohort with 10-year follow-up. OP0067, EULAR 2022, 1-4 June, Copenhagen, Denmark.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Antifibrotic therapy also effective in patients with negative prognostic factors for lung function decline Next Article
TYK2 inhibition: A rising star in lupus therapy? »
« Antifibrotic therapy also effective in patients with negative prognostic factors for lung function decline Next Article
TYK2 inhibition: A rising star in lupus therapy? »
Table of Contents: EULAR 2022
Featured articles
TYK2 inhibition: A rising star in lupus therapy?
JAK inhibitor shows to be effective in non-radiographic axSpA
Online First
Treatment with bimekizumab beneficial in psoriatic arthritis
IL-6 inhibition successful in treating polymyalgia rheumatica
High morbidity in pregnant lupus patients and their unborn children
Sexual dysfunction prevalent in RA and PsA patients
Fitness trackers reveal a low level of physical activity in patients with musculoskeletal disease
Global safety report data show more VTE events on JAK inhibition in RA
TYK2 inhibition: A rising star in lupus therapy?
Steep increase of mortality in RA patients with comorbid depression
Antifibrotic therapy also effective in patients with negative prognostic factors for lung function decline
Worse psychological symptoms in IBD patients with concomitant fibromyalgia
JAK inhibitor shows to be effective in non-radiographic axSpA
Tapering TNF blockers in axSpA and psoriatic arthritis: a successful approach
Baricitinib shows great potential in juvenile idiopathic arthritis
Unexpected comorbidity in patients with knee and hip osteoarthritis
RA: Several risk factors identified for incident dementia
Related Articles
February 26, 2021
App-based exercise program decreases knee osteoarthritis pain
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy